Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDFNASDAQ:GNTANASDAQ:IMMPNASDAQ:INZY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$3.16+1.9%$3.09$2.01▼$5.64$210.22M1.611.19 million shs1.46 million shsGNTAGenenta Science$3.05-0.3%$4.07$2.79▼$7.28$55.78M0.7315,158 shs4,397 shsIMMPPrima BioMed$1.52-5.0%$1.80$1.32▼$2.80$221.98M1.76207,673 shs285,510 shsINZYInozyme Pharma$3.99$2.61$0.72▼$6.24$257.60M2.291.47 million shs1.02 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology0.00%-18.64%+2.31%-18.21%+26.53%GNTAGenenta Science0.00%-20.67%-28.33%-23.34%-0.84%IMMPPrima BioMed0.00%-8.05%-17.53%-13.04%-41.61%INZYInozyme Pharma0.00%0.00%+0.76%+295.05%-10.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDFCardiff Oncology1.478 of 5 stars3.50.00.00.02.90.00.6GNTAGenenta Science3.0536 of 5 stars3.55.00.00.03.01.70.0IMMPPrima BioMed0.8544 of 5 stars3.51.00.00.00.00.00.0INZYInozyme Pharma2.6587 of 5 stars4.23.00.00.00.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDFCardiff Oncology 3.00Buy$12.00279.75% UpsideGNTAGenenta Science 3.00Buy$25.00719.67% UpsideIMMPPrima BioMed 3.00Buy$7.00360.53% UpsideINZYInozyme Pharma 2.44Hold$11.75194.49% UpsideCurrent Analyst Ratings BreakdownLatest GNTA, CRDF, INZY, and IMMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/16/2025INZYInozyme PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/16/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.005/16/2025INZYInozyme PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$15.00 ➝ $4.005/14/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/9/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.004/10/2025INZYInozyme PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/8/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDFCardiff Oncology$587K358.13N/AN/A$1.86 per share1.70GNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AIMMPPrima BioMed$5.14M43.19N/AN/A$1.05 per share1.45INZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDFCardiff Oncology-$45.43M-$0.92N/AN/AN/A-8,308.50%-76.45%-62.85%8/14/2025 (Estimated)GNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AIMMPPrima BioMed-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)INZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)Latest GNTA, CRDF, INZY, and IMMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/A5/8/2025Q1 2025CRDFCardiff Oncology-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDFCardiff OncologyN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDFCardiff OncologyN/A6.226.22GNTAGenenta ScienceN/A6.896.89IMMPPrima BioMedN/A18.86N/AINZYInozyme Pharma0.652.192.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDFCardiff Oncology16.29%GNTAGenenta Science15.13%IMMPPrima BioMed2.32%INZYInozyme Pharma88.30%Insider OwnershipCompanyInsider OwnershipCRDFCardiff Oncology7.70%GNTAGenenta Science28.99%IMMPPrima BioMed3.07%INZYInozyme Pharma12.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableIMMPPrima BioMed2,021146.04 million141.56 millionOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableGNTA, CRDF, INZY, and IMMP HeadlinesRecent News About These CompaniesInozyme Pharma Inc Ordinary SharesJune 21 at 5:46 PM | morningstar.comInozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of StockholdersJune 20 at 5:00 PM | globenewswire.comInozyme Pharma Reports Increased Loss Amid Strategic FocusJune 9, 2025 | tipranks.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of "Hold" from BrokeragesJune 9, 2025 | marketbeat.comMillennium Management LLC Has $5.21 Million Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)May 30, 2025 | marketbeat.comBMRN to Acquire Inozyme PharmaMay 22, 2025 | finance.yahoo.comINOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZYMay 21, 2025 | businesswire.comStockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&AMay 18, 2025 | genengnews.comJefferies Downgrades Inozyme Pharma (INZY)May 17, 2025 | msn.comNeedham Downgrades Inozyme Pharma (INZY)May 17, 2025 | msn.comLeerink bullish on BioMarin following Inozyme deal, expects additional BDMay 17, 2025 | finance.yahoo.comInozyme Shares More Than Double in Surge Toward BioMarin's Buyout PriceMay 16, 2025 | marketwatch.comBioMarin to buy rare disease drugmaker Inozyme for $270MMay 16, 2025 | biopharmadive.comBioMarin stock rises following Inozyme Pharma acquisitionMay 16, 2025 | in.investing.comBioMarin to Acquire Inozyme Pharma for $270MMay 16, 2025 | contractpharma.comBioMarin buys Inozyme for $270 millionMay 16, 2025 | thepharmaletter.comBioMarin to buy enzyme therapy developer Inozyme in $270M all-cash dealMay 16, 2025 | msn.comInozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment BrightensMay 16, 2025 | msn.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZYMay 16, 2025 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of ShareholdersMay 16, 2025 | prnewswire.comINZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to ShareholdersMay 16, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNTA, CRDF, INZY, and IMMP Company DescriptionsCardiff Oncology NASDAQ:CRDF$3.16 +0.06 (+1.94%) Closing price 04:00 PM EasternExtended Trading$3.17 +0.01 (+0.32%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Genenta Science NASDAQ:GNTA$3.05 -0.01 (-0.33%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Prima BioMed NASDAQ:IMMP$1.52 -0.08 (-5.00%) Closing price 04:00 PM EasternExtended Trading$1.54 +0.02 (+1.25%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Inozyme Pharma NASDAQ:INZY$3.99 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$4.00 +0.00 (+0.13%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
